
Expres²ion appoints CBO and IR partner

Expres²ion Biotechnologies ApS ("Expres²ion") has appointed Bent U. Frandsen, currently VP of Business Development, as Chief Business Officer (CBO). He will manage a proactive effort to substantially increase the customer base in the Company's vaccine development and production services segment. Furthermore, Expres²ion appoints Honeybadger as non-exclusive IR partner on the Swedish market.

The appointment of Bent U. Frandsen as CBO follows the strengthening of the Company's offer to provide complete services in vaccine development and GMP production to early clinical trials based on its Expres²-platform. The platform is currently used in several projects, including developing treatments for infectious diseases such as malaria and Ebola.

"We have recently added key technical and marketing personnel that has boosted the capacity in our core service segment significantly. Now, we also have a clearer company structure with Bent in overall charge of our sales, marketing and business development efforts," says Expres²ion's CEO Dr. Steen Klysner.

In addition to Bent U. Frandsen's appointment, the Company announces the appointment of Honeybadger as the Company's non-exclusive IR partner on the Swedish market. Honeybadger undertakes to assist Expres²ion in strategic communication as well as production of press releases, reports and non-regulatory market communication in Swedish and English. Expres²ion's relationship with Sedermera Fondkommission, the Company's Financial and Certified Advisor, is not affected by this and will continue to the same extent as before.

"With the capital received from the rights issue in the early spring, we have initiated a significant growth in operations. This has also increased the need for high-quality and transparent communication with our shareholders and the market. To meet this demand while keeping focus on our core activities, we have appointed Honeybadger, whom we have collaborated successfully with since the end of 2017, as our IR partner," says Expres²ion's CEO Dr. Steen Klysner.

About Honeybadger

Honeybadger AB is an IR communication agency based in Gothenburg, Sweden, that enables listed companies to communicate with shareholders, potential investors, media and other parties of interest in an efficient, qualitative and transparent way. The company focuses on clients that have the potential to improve the living conditions of humans, animals and nature through scientific and technological advances. Honeybadger is based on 15 years of experience in communication for listed companies and corporations in the financial sector.

Certified Adviser

Sedermera Fondkommission is appointed as Certified Adviser for Expres²ion.

For further information about Expres²ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: sk@expres2ionbio.com

About Expres²ion

Expres²ion Biotechnologies ApS is a fully owned Danish subsidiary of Expres²ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, Expres², that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, Expres²ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.